StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen accrued liabilities ($M) ($M)

Form 10-Q / 10-K (DB)

QuarterlyAnnual
Latest, Q2 2026
17,192
Period ended Jun 30, 2026
Change on a year earlier
+14.4%
15,022 in Q2 2025
History
62 quarters
Since Q4 2008
Sources
60
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAccrued liabilities ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202617,192+14.4%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202616,583-3.8%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 202518,523+5.0%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 202516,800+14.9%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 202515,022+9.5%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 202517,234+22.0%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 202417,641+14.9%Form 10-K (filed 2025-02-14) ↗
Q3 2024Sep 30, 202414,621+3.2%Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 202413,7220.0%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 202414,127+17.1%Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 202315,359+22.6%Form 10-K (filed 2024-02-14) ↗
Q3 2023Sep 30, 202314,168+22.3%Form 10-Q (filed 2023-10-31) ↗
Q2 2023Jun 30, 202313,718+30.1%Form 10-Q (filed 2023-08-04) ↗
Q1 2023Mar 31, 202312,061+13.4%Form 10-Q (filed 2023-04-28) ↗
Q4 2022Dec 31, 202212,524+16.7%Form 10-K (filed 2023-02-09) ↗
Q3 2022Sep 30, 202211,584+23.5%Form 10-Q (filed 2022-11-04) ↗

Cite this data

StockData. (2026). Amgen Accrued liabilities ($M) ($M), quarterly Q4 2008–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_accrued

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.